GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunflower Pharmaceutical Group Co Ltd (SZSE:002737) » Definitions » Cash Flow from Investing

Sunflower Pharmaceutical Group Co (SZSE:002737) Cash Flow from Investing : ¥-1,205 Mil (TTM As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sunflower Pharmaceutical Group Co Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2025, Sunflower Pharmaceutical Group Co spent ¥7 Mil on purchasing property, plant, equipment. It gained ¥0 Mil from selling property, plant, and equipment. It spent ¥0 Mil on purchasing business. It gained ¥0 Mil from selling business. It spent ¥1,760 Mil on purchasing investments. It gained ¥1,567 Mil from selling investments. It paid ¥0Mil for net Intangibles purchase and sale. And it paid ¥0 Mil for other investing activities. In all, Sunflower Pharmaceutical Group Co spent ¥200 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2025.


Sunflower Pharmaceutical Group Co Cash Flow from Investing Historical Data

The historical data trend for Sunflower Pharmaceutical Group Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunflower Pharmaceutical Group Co Cash Flow from Investing Chart

Sunflower Pharmaceutical Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -203.85 -889.72 -644.43 36.20 2.54

Sunflower Pharmaceutical Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,006.83 -530.76 -221.28 -252.26 -200.29

Sunflower Pharmaceutical Group Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Sunflower Pharmaceutical Group Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

Sunflower Pharmaceutical Group Co's Cash Flow from Investing for the quarter that ended in Mar. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1,205 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunflower Pharmaceutical Group Co  (SZSE:002737) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Sunflower Pharmaceutical Group Co's purchase of property, plant, equipment for the three months ended in Mar. 2025 was ¥-7 Mil. It means Sunflower Pharmaceutical Group Co spent ¥7 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Sunflower Pharmaceutical Group Co's sale of property, plant, equipment for the three months ended in Mar. 2025 was ¥0 Mil. It means Sunflower Pharmaceutical Group Co gained ¥0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Sunflower Pharmaceutical Group Co's purchase of business for the three months ended in Mar. 2025 was ¥0 Mil. It means Sunflower Pharmaceutical Group Co spent ¥0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Sunflower Pharmaceutical Group Co's sale of business for the three months ended in Mar. 2025 was ¥0 Mil. It means Sunflower Pharmaceutical Group Co gained ¥0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Sunflower Pharmaceutical Group Co's purchase of investment for the three months ended in Mar. 2025 was ¥-1,760 Mil. It means Sunflower Pharmaceutical Group Co spent {stock_data.stock.currency_symbol}}1,760 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Sunflower Pharmaceutical Group Co's sale of investment for the three months ended in Mar. 2025 was ¥1,567 Mil. It means Sunflower Pharmaceutical Group Co gained ¥1,567 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Sunflower Pharmaceutical Group Co's net Intangibles purchase and sale for the three months ended in Mar. 2025 was ¥0 Mil. It means Sunflower Pharmaceutical Group Co paid ¥0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Sunflower Pharmaceutical Group Co's cash from discontinued investing activities for the three months ended in Mar. 2025 was 0 Mil. It means Sunflower Pharmaceutical Group Co paid ¥0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Sunflower Pharmaceutical Group Co's cash from other investing activities for the three months ended in Mar. 2025 was ¥0 Mil. It means Sunflower Pharmaceutical Group Co paid ¥0 Mil for other investing activities.


Sunflower Pharmaceutical Group Co Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Sunflower Pharmaceutical Group Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunflower Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
Welcome Road, 18 East Lake Road, Harbin High-Tech Industrial Development Zone, Harbin, Heilongjiang, CHN
Sunflower Pharmaceutical Group Co Ltd is engaged in pharmaceutical manufacturing, marketing, and scientific research. The company's product profile include Honeysuckle, Weikangling Granules, Autumn pear moisturizing cream, Vitamin AD drops, Pediatric paracetamol granules, Jianweixiaoshi tablets, Pediatric Chai Gui Antipyretic Granules, Pediatric cough syrup, Kang Fu anti-inflammatory suppository, Xiangsha Yangwei Pills, and others.
Executives
Zhou Jian Zhong Executives
Liu Tian Wei Director
Guan Yu Xiu Director
Wu Guo Xiang Executives
Ren Jing Shang Directors, executives
Guan Yan Bin Directors, executives
Wan Yun Guo Executives
Tian Yan Secretary Dong
Tan Chang Executives
Zhang Quan Director
Xu Qing Fen Supervisors
Jiang Feng He Supervisors
Wu Shu Hua Director
Guan Yan Ling Director

Sunflower Pharmaceutical Group Co Headlines

No Headlines